leading brands of glp-1 agonists in biopharma Latin America Glucagon-like Peptide-1 Market - Comparing Ozempic, Wegovy and Other
Description
Muller TD, Finan B, Bloom SR, DAlessio D, Drucker DJ, Flatt PR, et al
STEP series clinical trials of Semaglutide Novo's two obesity products, Wegovy and Saxenda, have generated DKK 16.86bn (USD 2.5bn) in sales throughout 2022, doubling the preceding year's result of DKK 8.4bn (USD 1.2bn) an increase of 101%
Medication Interactions: If you are already taking insulin or other diabetes medications, the risk of hypoglycemia (low blood sugar) increases
Cost may also be a barrier to wide GLP-1RA adoption, according to 93 percent of physicians surveyed
